Dr. Tripathy Discusses Lurbinectedin in Breast Cancer

Debu Tripathy, MD
Published: Thursday, Dec 14, 2017



Debu Tripathy, MD, professor of medicine, chair, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses lurbinectedin (PM01183) for patients with breast cancer.

According to Tripathy, lurbinectedin affects how DNA divides. This was tested in patients with breast cancer who had BRCA1/2 mutations and was found to be active and lead to temporary progressions. The trial was amended to include patients with BRCA1/2 mutations who had received a prior PARP inhibitor.

Randomized trials are needed to compare lurbinectedin with other treatments, such as PARP inhibitors. Research is also needed to determine if the regimen can be combined to demonstrate an even higher benefit, explains Tripathy.
 


Debu Tripathy, MD, professor of medicine, chair, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses lurbinectedin (PM01183) for patients with breast cancer.

According to Tripathy, lurbinectedin affects how DNA divides. This was tested in patients with breast cancer who had BRCA1/2 mutations and was found to be active and lead to temporary progressions. The trial was amended to include patients with BRCA1/2 mutations who had received a prior PARP inhibitor.

Randomized trials are needed to compare lurbinectedin with other treatments, such as PARP inhibitors. Research is also needed to determine if the regimen can be combined to demonstrate an even higher benefit, explains Tripathy.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Cancer Summaries and Commentaries™: Update from Chicago: Advances in the Treatment of Breast CancerJul 31, 20181.0
Community Practice Connections™: Medical Crossfire®: Translating Lessons Learned with PARP Inhibition to the Treatment of Breast Cancer—Expert Exchanges on Novel Strategies to Personalize CareAug 29, 20181.5
Publication Bottom Border
Border Publication
x